RE:RE:RE:RE:news nov 28tibutch1- I tried to read and understand your post but I lost track of your message (I counted 97 words in that sentence). "The other real developments is there pre clinical trials the results are there and confirmed 3 times at that so there is a timeline before it goes to the next level trial but usually in biotechs that next step level 1 trials is not to long which could be very rewarding for the stock price which would leverage out less dilution in the future for R&D work, one step at time, laser therapy as evolved at a very rapid pace over the last 3 years and there will more to come, as some would say the race is on". Here's the deal. That financing update at $2.1 million was , as you say, at end 3rd Q (Sep 30). If you reviewed their updated personnel list, you'll see over 20 people in their support team (if you were only paying them 40k/year + benefits then we easily exceed $1 mill per year and I'm not including top officers). In short, they need to launch the TLC2000 now to generate support revenue. If there is an HC approval delay then they should have just told us it is pending w/expected approval in Dec or early Jan... but be straightforward. I'm here for the cancer side of the business but the 1st step from this day forward has to be getting the HC approval for TLC2000 followed by the U of T rat results in Dec or very early Jan.